ADVFN ADVFN

Hot Features

Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Harrow Inc

Harrow Inc (HROW)

33,19
-1,50
(-4,32%)
Fermé 07 Juin 10:00PM
33,00
-0,19
(-0,57%)
Après les heures de négociation: 1:23AM

Harrow Inc (HROW) Action

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Statistiques et détails clés

Dernier
33,00
( -4,87% )
Prix Achat
25,58
Prix Vente
42,02
Volume échangé
649 521
33,10 Fourchette du Jour 34,90
27,755 Plage de 52 semaines 54,85
Cap du marché
Clôture Veille
34,69
Ouverture
34,59
Dernière Transaction
4
@
33.06
Dernière heure de transaction
Volume financier
US$ 22 132 937
VWAP
34,0758
Volume moyen (3 m)
US$ 870 444
Actions en circulation
37 275 107
Rendement du Dividende (LTM)
Ratio Cours sur Bénéfices
-84,61
Bénéfice par action (BPA)
-0,4
Chiffre d'affairess (LTM)
268,68M
Bénéfice net (LTM)
-14,96M

À propos de Harrow Inc

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medication... Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee. Show more

Secteur
Healthcare
Industrie
Pharmaceuticals
Site Web
Siège social
Nashville, United States
Fondé
1998
Harrow Inc est coté dans le secteur Healthcare de la NASDAQ avec le ticker HROW. Le dernier cours de clôture d'Harrow était de US$34,69. Au cours de la dernière année, les actions de Harrow ont été négociées dans une fourchette de prix de US$ 27,755 à US$ 54,85.

Harrow compte actuellement 37 275 107 actions en circulation. La capitalisation boursière d'Harrow est de US$1,23 milliard. Harrow a un ratio cours/bénéfice (ratio PE) de -84.61.

Flux d'options Harrow (HROW)

Flux global

Haussier

Prime nette

590k

Calls / Puts

100,00%

Ach. / Vent.

7,69%

OTM / ITM

7,69%

Sweeps Ratio

0,00%

HROW Dernières nouvelles

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-2.29-6.4890903938835.2935.8732.4568796434.10387242CS
4-6.1-15.601023017939.139.8428.5401112172432.16528015CS
12-2.8-7.8212290502835.842.1328.540172931634.67668232CS
26-13.7-29.336188436846.754.8528.540171945640.17873711CS
523.4111.524163568829.5954.8527.75566757539.35630622CS
15613.569.230769230819.559.237.656873829.52437453CS
26023.72255.6034482769.2859.235.442056026.52488252CS

HROW - Frequently Asked Questions (FAQ)

What is the current Harrow Inc share price?
The current share price of Harrow Inc is US$ 33,00
How many Harrow Inc shares are in issue?
Harrow Inc has 37 275 107 shares in issue
What is the market cap of Harrow Inc?
The market capitalisation of Harrow Inc is USD 1,23B
What is the 1 year trading range for Harrow Inc share price?
Harrow Inc has traded in the range of US$ 27,755 to US$ 54,85 during the past year
What is the PE ratio of Harrow Inc?
The price to earnings ratio of Harrow Inc is -84,61
What is the cash to sales ratio of Harrow Inc?
The cash to sales ratio of Harrow Inc is 4,73
What is the registered address of Harrow Inc?
The registered address for Harrow Inc is 1A Burton Hills Boulevard, Nashville, Tennessee, 37215
What is the Harrow Inc website address?
The website address for Harrow Inc is www.harrow.com
Which industry sector does Harrow Inc operate in?
Harrow Inc operates in the Pharmaceuticals sector

HROW Transactions

Plus

Transactions différées

Pour obtenir des transactions en temps réel, améliorez votre compte

Passer à la version en temps réel
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock